(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 July 2017 (06.07.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/116066 A1

(51) **International Patent Classification**:
A61K 38/43 (2006.01) *A61K 9/00* (2006.01)

(21) **International Application Number**:
PCT/KR2016/015060

(22) **International Filing Date**:
21 December 2016 (21.12.2016)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
62/272,843 30 December 2015 (30.12.2015) US
62/369,970 2 August 2016 (02.08.2016) US

(71) **Applicants**: **GREEN CROSS CORPORATION** [KR/KR]; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **MEDIGENEBIO CORPORATION** [KR/KR]; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR).

(72) **Inventors**: **OKUYAMA, Torayuki**; 2-10-1, Okura, Setagaya-ku, Tokyo, Tokyo 157-8535 (JP). **JIN, Thong-Gyu**; E-3806, 57, Eonju-ro 30-gil, Seoul 06293 (KR). **BYUN, Han-Yeul**; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **SEO, Jin-Wook**; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **LEE, Byoung-Ju**; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **KIM, Yong-Chul**; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **JANG, In-Young**; (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR).

(74) **Agent**: **DOOHO IP LAW FIRM**; (Seocho-dong, Daehyun Blue Tower) 7th Floor, 1, Gangnam-daero 51-gil, Seocho-gu, Seoul 06628 (KR).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2017/116066 A1

(54) **Title**: METHODS AND COMPOSITIONS FOR TREATING HUNTER SYNDROME



(57) **Abstract**: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.